- Home
- AEYE vs CABA Comparison
AEYE vs CABA Comparison
Compare AEYE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- CABA
- Stock Information
- Founded
- AEYE 2005
- CABA 2017
- Country
- AEYE United States
- CABA United States
- Employees
- AEYE N/A
- CABA N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEYE Technology
- CABA Health Care
- Exchange
- AEYE Nasdaq
- CABA Nasdaq
- Market Cap
- AEYE 154.6M
- CABA 132.6M
- IPO Year
- AEYE N/A
- CABA 2019
- Fundamental
- Price
- AEYE $13.49
- CABA $1.68
- Analyst Decision
- AEYE Strong Buy
- CABA Strong Buy
- Analyst Count
- AEYE 4
- CABA 8
- Target Price
- AEYE $25.25
- CABA $12.75
- AVG Volume (30 Days)
- AEYE 96.3K
- CABA 1.5M
- Earning Date
- AEYE 11-06-2025
- CABA 08-07-2025
- Dividend Yield
- AEYE N/A
- CABA N/A
- EPS Growth
- AEYE N/A
- CABA N/A
- EPS
- AEYE N/A
- CABA N/A
- Revenue
- AEYE $38,238,000.00
- CABA N/A
- Revenue This Year
- AEYE $17.16
- CABA N/A
- Revenue Next Year
- AEYE $17.77
- CABA N/A
- P/E Ratio
- AEYE N/A
- CABA N/A
- Revenue Growth
- AEYE 18.53
- CABA N/A
- 52 Week Low
- AEYE $8.91
- CABA $0.99
- 52 Week High
- AEYE $34.85
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- AEYE 62.24
- CABA 55.89
- Support Level
- AEYE $11.93
- CABA $1.44
- Resistance Level
- AEYE $14.29
- CABA $1.74
- Average True Range (ATR)
- AEYE 0.66
- CABA 0.10
- MACD
- AEYE 0.17
- CABA 0.02
- Stochastic Oscillator
- AEYE 74.14
- CABA 79.41
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.